UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
April 5, 2005
----------------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-15190 13-3159796
---------------- ------- --------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 South Service Road
Melville, NY 11747
--------------------------
(Address of principal executive offices)
(631) 962-2000
---------------------
(Registrant's telephone number, including area code)
N/A
-----------
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a- 12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
Effective April 5, 2005, Genentech, Inc., OSI Pharmaceuticals, Inc.'s
partner for the distribution and sale in the United States of its oncology drug,
Tarceva(TM), is implementing a price increase to wholesalers for sales of the
drug in the United States. The price for a 30-day supply of 150 mg tablets will
increase from the launch price of $2,026 to $2,330. The prices for a 30-day
supply of the 100 mg and 25 mg tablet strengths will increase from $1,783 to
$2,060 and $648 to $750, respectively.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 5, 2005 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
3